Antares Pharma (ATRS) Misses Q3 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $11.15 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• Morgan Stanley refreshes Strait of Hormuz reopening analysis